Arcutis Biotherapeutics Inc is a medical dermatology company... Show more
ARQT moved below its 50-day moving average on January 12, 2026 date and that indicates a change from an upward trend to a downward trend. In of 42 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
The 10-day RSI Indicator for ARQT moved out of overbought territory on December 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 67 cases where ARQT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on January 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARQT as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ARQT turned negative on December 09, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .
ARQT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 211 cases where ARQT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.202) is normal, around the industry mean (26.435). P/E Ratio (0.000) is within average values for comparable stocks, (51.296). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.883). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (10.352) is also within normal values, averaging (324.813).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
a company, which engages in the development and commercialization of treatments for dermatological diseases.
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FRGOX | 42.28 | 0.03 | +0.07% |
| Franklin Gold and Precious Metals C | |||
| PEXMX | 36.76 | -0.02 | -0.05% |
| T. Rowe Price Extended Equity Market Idx | |||
| WDIIX | 15.04 | -0.05 | -0.33% |
| Wilmington Enhanced Div Inc Strat I | |||
| AULNX | 108.95 | -0.36 | -0.33% |
| American Century Ultra® G | |||
| MINVX | 29.03 | -0.14 | -0.48% |
| Madison Large Cap Y | |||
A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with IDYA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then IDYA could also see price increases.
| Ticker / NAME | Correlation To ARQT | 1D Price Change % | ||
|---|---|---|---|---|
| ARQT | 100% | -2.73% | ||
| IDYA - ARQT | 46% Loosely correlated | -4.75% | ||
| XNCR - ARQT | 42% Loosely correlated | -1.62% | ||
| NUVL - ARQT | 42% Loosely correlated | +2.03% | ||
| XENE - ARQT | 41% Loosely correlated | -2.11% | ||
| DNLI - ARQT | 40% Loosely correlated | +0.89% | ||
More | ||||